Candel Therapeutics (CADL) to Release Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Candel Therapeutics (NASDAQ:CADL) last posted its earnings results on Thursday, March 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.17). On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Candel Therapeutics Price Performance

Shares of CADL opened at $8.22 on Wednesday. The firm has a fifty day moving average price of $8.24 and a 200 day moving average price of $7.06. The stock has a market cap of $266.95 million, a PE ratio of -4.75 and a beta of -1.29. Candel Therapeutics has a 1-year low of $1.45 and a 1-year high of $14.60.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 31,278 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $8.82, for a total transaction of $275,871.96. Following the completion of the transaction, the chief technology officer now owns 85,512 shares in the company, valued at approximately $754,215.84. This represents a 26.78 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Francesca Barone sold 13,534 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total transaction of $97,715.48. Following the completion of the sale, the insider now owns 110,673 shares of the company’s stock, valued at $799,059.06. This trade represents a 10.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 77,807 shares of company stock valued at $633,534 in the last ninety days. Insiders own 41.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on CADL shares. Citigroup started coverage on Candel Therapeutics in a research report on Thursday, February 20th. They issued a “buy” rating and a $25.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Candel Therapeutics in a report on Friday, March 14th. Bank of America started coverage on shares of Candel Therapeutics in a report on Friday, February 7th. They issued a “buy” rating and a $15.00 target price on the stock. Finally, Canaccord Genuity Group increased their price target on shares of Candel Therapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.